3D pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Vilar, Santiago ^a   Tatonetti, Nicholas P ^a   Hripcsak, George ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ADVERSE DRUG REACTION; CHEMISTRY; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; HUMAN; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; THEORETICAL MODEL;

DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84924587569     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08809     Document Type: Article

References (35)

1. Bates, D. W. et al. The costs of adverse drug events in hospitalized patients. JAMA 277, 307-311 (1997).
2. Wu, C., Bell, C. M. & Wodchis, W. P. Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments A Retrospective Study. Drug Saf. 35, 769-781 (2012).
3. Bass, A. S. et al. Exploratory drug safety: A discovery strategy to reduce attrition in development. J. Pharmacol. Toxicol. Methods 60, 69-78 (2009).
4. Kuhn, M. et al. Systematic identification of proteins that elicit drug side effects. Mol. Syst. Biol. 9, 663 (2013).
5. Wallach, I., Jaitly, N. & Lilien, R. A. Structure-Based Approach for Mapping Adverse Drug Reactions to the Perturbation of Underlying Biological Pathways. PLOS ONE 5, e12063 (2010).
6. Lounkine, E. et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361-7 (2012).
7. Valerio, L. G. Jr. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 241, 356-370 (2009).
8. Benigni, R. & Bossa, C. Predictivity and reliability of QSAR models: The case of mutagens and carcinogens. Toxicol. Mech. Methods 18, 137-147 (2008).
9. Jensen, G. E., Niemela, J. R., Wedebye, E. B. & Nikolov, N. G. QSAR models for reproductive toxicity and endocrine disruption in regulatory use-a preliminary investigation. SAR QSAR Environ. Res. 19, 631-641 (2008).
10. Segall, M. D., Beresford, A. P., Gola, J. M. R., Hawksley, D. & Tarbit, M. H. Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery. Expert Opin. Drug Metab. Toxicol. 2, 325-337 (2006).
11. Vilar, S., Chakrabarti, M. & Costanzi, S. Prediction of passive blood-brain partitioning: Straightforward and effective classification models based on in silico derived physicochemical descriptors. J. Mol. Graph. Model. 28, 899-903 (2010).
12. Valerio, L. G. Jr. In silico toxicology models and databases as FDA Critical Path Initiative toolkits. Hum. Genomics 5, 200-207 (2011).
13. Scheiber, J. et al. Mapping Adverse Drug Reactions in Chemical Space. J. Med. Chem. 52, 3103-3107 (2009).
14. Bender, A. et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2, 861-873 (2007).
15. Pauwels, E., Stoven, V. & Yamanishi, Y. Predicting drug side-effect profiles: a chemical fragment-based approach. BMC Bioinformatics 12, 169 (2011).
16. Vilar, S. et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J. Am. Med. Inform. Assoc. 18, I73-I80 (2011).
17. Vilar, S., Harpaz, R., Santana, L., Uriarte, E. & Friedman, C. Enhancing Adverse Drug Event Detection in Electronic Health Records Using Molecular Structure Similarity: Application to Pancreatitis. PLOS ONE 7, e41471 (2012).
18. FDA U. S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). Available at: http://www.fda.gov/cder/aers/default.htm (Accessed: Jun 2013).
19. Harpaz, R. et al. Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System. Clin. Pharmacol.Ther. 93, 539-546 (2013).
20. Hauben, M. & Bate, A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov. Today 14, 343-357 (2009).
21. Harpaz, R. et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J. Am. Med. Inform. Assoc. 20, 413-419 (2013).
22. Ryan, P. B., Madigan, D., Stang, P. E., Schuemie, M. J. & Hripcsak, G. Medication-Wide Association Studies. CPT: Pharmacometrics Syst. Pharmacol. 2, e76 (2013).
23. Almenoff, J. S., LaCroix, K. K., Yuen, N. A., Fram, D. & DuMouchel, W. Comparative performance of two quantitative safety signalling methods-Implications for use in a pharmacovigilance department. Drug Saf. 29, 875-887 (2006).
24. Vilar, S. et al. Similarity-based modeling applied to signal detection in pharmacovigilance. CPT Pharmacometrics Syst. Pharmacol. 3, e137 (2014).
25. SIDER Side Effect Resource. Available at: http://sideeffects.embl.de/(Accessed: May 2013).
26. DrugBank database, version 3.0. Available at: http://www.drugbank.ca/(Accessed: Jul 2013).
27. Tatonetti, N. P., Ye, P. P., Daneshjou, R. & Altman, R. B. Data-Driven Prediction of Drug Effects and Interactions. Sci. Transl. Med. 4, 125ra31 (2012).
28. Durant, J. L., Leland, B. A., Henry, D. R. & Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 42, 1273-1280 (2002).
29. Todeschini, R. & Consonni, V. Handbook of Molecular Descriptors. Wiley-VCH, Weinheim, (Germany), 2000.
30. The PubChem Project. Available at: http://pubchem.ncbi.nlm.nih.gov/(Accessed: Jul 2014).
31. Bolton, E. E. et al. PubChem3D: a new resource for scientists. J. Cheminform. 3, 32 (2011).
32. Kim, S., Bolton, E. E. & Bryant, S. H. PubChem3D: Biologically relevant 3-D similarity. J. Cheminform. 3, 26 (2011).
33. Vilar, S., Uriarte, E., Santana, L., Friedman, C. & Tatonetti, N. P. State of the Art and Development of a Drug-Drug Interaction Large Scale Predictor Based on 3D Pharmacophoric Similarity. Curr. Drug Metab. 15, 490-501 (2014).
34. Vieth, M., Hirst, J. D. & Brooks, C. L. Do active site conformations of small ligands correspond to low free-energy solution structures? J. Comput. Aided Mol. Des. 12, 563-572 (1998).
35. RCSB Protein Data Bank. Available at: http://www.rcsb.org/(Accessed: Dec 2014).